• Product NameDuvelisib (IPI-145, INK1197)
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityDuvelisib (IPI-145, INK1197) is a novel and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM in cell-free assays, highly selective for PI3K δ/γ than other protein kinases. Phase 3.
• Target NamePI3K inhibitor
• CAS No. 1201438-56-3
• Calculated MW 416.86
• Formulation C22H17ClN6O
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
  Pathways:PI3K/Akt/mTOR signaling
  Receptor:PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ
  Boling pt:
  Melting pt:
  Solubility:DMSO: 83 mg/mL (199.1 mM)
  Appearance:WhitePowder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Vito Palombella, Targeting PI3K- δ and PI3K-γ in Inflammation, 2012.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting